- Home
- KWE vs REVB Comparison
KWE vs REVB Comparison
Compare KWE & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KWE
- REVB
- Stock Information
- Founded
- KWE 2017
- REVB 2020
- Country
- KWE Canada
- REVB United States
- Employees
- KWE N/A
- REVB N/A
- Industry
- KWE
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- KWE
- REVB Health Care
- Exchange
- KWE Nasdaq
- REVB Nasdaq
- Market Cap
- KWE 2.3M
- REVB 2.6M
- IPO Year
- KWE N/A
- REVB N/A
- Fundamental
- Price
- KWE $5.14
- REVB $3.05
- Analyst Decision
- KWE
- REVB
- Analyst Count
- KWE 0
- REVB 0
- Target Price
- KWE N/A
- REVB N/A
- AVG Volume (30 Days)
- KWE 559.4K
- REVB 39.6K
- Earning Date
- KWE 05-23-2025
- REVB 05-08-2025
- Dividend Yield
- KWE N/A
- REVB N/A
- EPS Growth
- KWE N/A
- REVB N/A
- EPS
- KWE N/A
- REVB N/A
- Revenue
- KWE $1,572,738.00
- REVB N/A
- Revenue This Year
- KWE N/A
- REVB N/A
- Revenue Next Year
- KWE N/A
- REVB N/A
- P/E Ratio
- KWE N/A
- REVB N/A
- Revenue Growth
- KWE 116.30
- REVB N/A
- 52 Week Low
- KWE $0.22
- REVB $2.36
- 52 Week High
- KWE $243.60
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- KWE 47.83
- REVB 49.28
- Support Level
- KWE $5.15
- REVB $2.87
- Resistance Level
- KWE $7.10
- REVB $3.32
- Average True Range (ATR)
- KWE 0.73
- REVB 0.20
- MACD
- KWE 0.10
- REVB 0.02
- Stochastic Oscillator
- KWE 31.15
- REVB 47.18
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).